Head-to-head · free
SOPHiA GENETICS S.A. vs Stryker Corporation
SOPH vs SYK — return on capital, cash generation, margins and balance sheet side by side.
SOPH
2 / 4
measures where SOPH leads
SYK
2 / 4
measures where SYK leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | SOPH | SYK · FY2025 |
|---|---|---|
| Revenue | — | $5.9B |
| Net income | — | $654.0M |
| Revenue growth (yearly, multi-year) | — | 10.4% |
| Free cash flow | — | $4.3B |
| Free cash flow margin | — | 73.0% |
| Net cash / (debt) | — | — |
| ROIC | — | 9.6% |
| Return on equity | -110.0% | 15.1% |
| Gross margin | 67.4% | 64.0% |
| Operating margin | -91.8% | 20.1% |
| Net debt / EBITDA | 0.37x | 1.95x |
Figures are as reported by each company; latest fiscal year shown.
Where Stryker Corporation's cash went (FY2025)
- Capital spending
- $761.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free